RDNZ supports Pharmac's proposal to fund risdiplam for SMA

23 Feb 2023

None

Rare Disorders NZ has made a submission to Pharmac on the proposal, expressing support for the funding proposal for Risdiplam which we understand would have the same access criteria as nusinersen (Spinraza).

Rare Disorders NZ supports two funded options for the treatment of symptomatic SMA in New Zealand, especially as Risdiplam would provide an oral treatment option alongside nusinersen.

None

None

Our Collective

Rare Disorders NZ is the collective voice of all people living with a rare disorder and their whānau. Our rare collective is made up of more than 150 disorder-specific support groups.

Our work is informed by the issues important to our collective. We work together to improve healthcare and wellbeing for everyone living with a rare health condition in New Zealand.

Learn more